Biotech Industry Forms International Council - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biotech Industry Forms International Council


The Biotechnology Industry Organization (BIO) is reporting that an international confederation of biotechnology trade associations has created the International Council on Biotechnology Associations (ICBA) to advocate for public policies that support worldwide biotechnology growth. BIO’s president and CEO, Jim Greenwood, has been elected to serve as ICBA Chairman, and Nathalie Moll, secretary general of EuropaBio, was elected Vice Chair.

“The increasingly global biotechnology industry provides breakthrough products and technologies that combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes,” said Greenwood in a press release. “However, the biotechnology sector faces both challenges and opportunities that cross borders.  In forming the ICBA, our industry is taking an important step that allows us to better coordinate, organize and face these issues around the world together."

“Biotechnology is geared at enhancing our quality of life and responding to society’s grand challenges such as an ageing and ever increasing population, healthcare choice and affordability, resource efficiency, food security, climate change, energy shortages and economic growth,” said Moll in the press release. “The ICBA will advocate for more efficient and effective governance, science-based regulatory systems and the right framework conditions for competitiveness and innovation to ensure faster and more equitable access to biotech products and processes for patients, farmers and consumers around the world.”

Source: BIO.org

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here